drugset / Trial / NCT01133184

Improved Prevention of Perinatal Hepatitis B Transmission

NCT01133184

Phase 4 Unknown 6343 enrolled Hadassah Medical Organization
RandomizedFactorialSingle-blindPrevention

Summary

Impaired activity of Natural Killer (NK) cells has been proposed as a mechanism contributing to viral persistence in Hepatitis C Virus (HCV) infection. NK cells display anti-fibrotic activities by killing activated hepatic stellate cells (HSCs) that have lost the self-recognition marker; Major Histocompatibility (MHC) class I. Determining the down-expressed genes on NK cells necessary for their anti-fibrotic activity was never studied previously. This will allow us to study their role fully in phagocytosis process as well as their interaction of HSCs and therefore manipulating these genes using molecular techniques. Exploring the cellular functions of these genes will highlight their involvement in the progression of liver fibrosis and could be used as a therapeutic tool for preventing the disease.

Timeline

Start
2010-09
Primary completion
2011-03
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sci-B-Vac Vaccine